[Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19].
Ter Arkh
; 96(5): 517-522, 2024 Jun 03.
Article
en Ru
| MEDLINE
| ID: mdl-38829814
ABSTRACT
AIM:
To evaluate the efficacy and safety of riamilovir in the treatment of COVID-19 in adults. MATERIALS ANDMETHODS:
The study included 180 patients with a laboratory-confirmed diagnosis of COVID-19 which fully meet the criteria for inclusion, non-inclusion and exclusion, signed a voluntary informed consent to participate in a clinical trial.RESULTS:
The efficacy, good tolerability and safety of the drug riamilovir in the treatment of COVID-19 have been established.CONCLUSION:
As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Tratamiento Farmacológico de COVID-19
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Ru
Revista:
Ter Arkh
Año:
2024
Tipo del documento:
Article